Brian Mendelsohn
Independent Consultant Independent Consultant
Dr. Brian A. Mendelsohn significantly contributed to ADC technology at Seattle Genetics (2000-2005), synthesizing the first MMAE drug molecule. He completed his Ph.D. in chemistry at the University of British Columbia in 2005, focusing on natural product toxin synthesis. He then established and led the ADC Chemistry group at Agensys (2011-2017), served as Director at Ajinomoto Bio-Pharma Services (2018-2020), and is currently Executive Director of ADCs at Exelixis, Inc. He received the ACS Heroes of Chemistry Award (2018) and the George R. Pettit Award (2024).
Seminars
Thursday 6th November 2025
Workshop highlights include:
- Discussing the growing need for novel ADC payloads in the face of ADC patient resistance mechanisms
- Weighing up the pros and cons of novel cytotoxic, catalytic, oligonucleotide, and immune-stimulating payload safety and efficacy
- Assessing MoA characterization of ADC payloads beyond classical cytotoxic agents
